Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Barriers to the effective treatment of sepsis: antimicrobial agents, sepsis definitions, and host-directed therapies.

Lyle NH, Pena OM, Boyd JH, Hancock RE.

Ann N Y Acad Sci. 2014 Sep;1323:101-14. doi: 10.1111/nyas.12444. Epub 2014 May 2. Review.

PMID:
24797961
2.

Impact of antimicrobial resistance on the treatment and outcome of patients with sepsis.

Figueiredo Costa S.

Shock. 2008 Oct;30 Suppl 1:23-9. doi: 10.1097/SHK.0b013e3181818990. Review.

PMID:
18704013
3.

A blueprint for a sepsis protocol.

Shapiro NI, Howell M, Talmor D.

Acad Emerg Med. 2005 Apr;12(4):352-9.

4.

Optimal antimicrobial therapy for sepsis.

Fish DN.

Am J Health Syst Pharm. 2002 Feb 15;59 Suppl 1:S13-9. Review.

PMID:
11885408
5.

New therapies for sepsis.

Cunnington A, Nadel S.

Curr Top Med Chem. 2008;8(7):603-14.

PMID:
18473886
6.
7.

Adjunctive therapies for severe sepsis.

Wittebole X, Collienne C, Castanares-Zapatero D, Laterre PF.

Int J Antimicrob Agents. 2008 Nov;32 Suppl 1:S34-8. doi: 10.1016/j.ijantimicag.2008.06.005. Epub 2008 Aug 19. Review.

PMID:
18715758
8.

Anti-inflammatory therapies in sepsis and septic shock.

Freeman BD, Natanson C.

Expert Opin Investig Drugs. 2000 Jul;9(7):1651-63. Review.

PMID:
11060768
9.

A new paradigm for the treatment of sepsis: is it time to consider combination therapy?

Cross AS, Opal SM.

Ann Intern Med. 2003 Mar 18;138(6):502-5. Review.

PMID:
12639085
10.

Lack of evidence for qualitative treatment by disease severity interactions in clinical studies of severe sepsis.

Macias WL, Nelson DR, Williams M, Garg R, Janes J, Sashegyi A.

Crit Care. 2005;9(6):R607-22. Epub 2005 Sep 22. Review.

11.
12.

Emerging therapies for sepsis and septic shock.

Oh HM.

Ann Acad Med Singapore. 1998 Sep;27(5):738-43. Review.

PMID:
9919353
13.

Infection in critically ill patients: clinical impact and management.

Vincent JL, Jacobs F.

Curr Opin Infect Dis. 2003 Aug;16(4):309-13. Review.

PMID:
12861083
14.

The staging of sepsis: understanding heterogeneity in treatment efficacy.

Marshall JC.

Crit Care. 2005;9(6):626-8. Epub 2005 Nov 22.

15.

An alternate pathophysiologic paradigm of sepsis and septic shock: implications for optimizing antimicrobial therapy.

Kumar A.

Virulence. 2014 Jan 1;5(1):80-97. doi: 10.4161/viru.26913. Epub 2013 Nov 1. Review.

16.

The use of activated protein C (drotrecogin alfa (activated)) in the treatment of severe sepsis.

Murgo M, Adamson H, Boyle M.

Aust Crit Care. 2003 Nov;16(4):133-43. Review.

PMID:
14692158
17.

Selection of antimicrobial agents for treatment of neonatal sepsis.

Klein JO, Dashefsky B, Norton CR, Mayer J.

Rev Infect Dis. 1983 Mar-Apr;5 Suppl 1:S55-64. Review.

PMID:
6342099
18.

Neonatal sepsis at Muhimbili National Hospital, Dar es Salaam, Tanzania; aetiology, antimicrobial sensitivity pattern and clinical outcome.

Mhada TV, Fredrick F, Matee MI, Massawe A.

BMC Public Health. 2012 Oct 24;12:904. doi: 10.1186/1471-2458-12-904.

19.

Management of sepsis in the critically ill patient: key aspects.

Vincent JL.

Expert Opin Pharmacother. 2006 Oct;7(15):2037-45. Review.

PMID:
17020431
20.

The design and implementation of trials of host modulation agents.

Offenbacher S, Salvi GE, Beck JD, Williams RC.

Ann Periodontol. 1997 Mar;2(1):199-212.

PMID:
9151554
Items per page

Supplemental Content

Write to the Help Desk